<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058343</url>
  </required_header>
  <id_info>
    <org_study_id>IFN-K-001</org_study_id>
    <nct_id>NCT01058343</nct_id>
  </id_info>
  <brief_title>Safety of IFNa Kinoid in Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovacs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovacs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus
      (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be
      an attractive therapeutic strategy. Active immunization with IFNa kinoid (IFN-K) induces a
      polyclonal antibody response.

      This study will evaluate the safety of IFN-K in patients with mild to moderate SLE. It will
      also measure the induction of anti-IFNa antibodies and evaluate the clinical impact on SLE
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with anti IFNa antibodies</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>IFN-K 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN kinoid dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN-K-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN kinoid dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN-K 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN kinoid dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN-K 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN kinoid dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline at same dose as IFN K</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFN-K</intervention_name>
    <description>3 to 4 IM injections over 3 months</description>
    <arm_group_label>IFN-K 1</arm_group_label>
    <arm_group_label>IFN-K-2</arm_group_label>
    <arm_group_label>IFN-K 3</arm_group_label>
    <arm_group_label>IFN-K 4</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Diagnosis of SLE according to current American College of Rheumatology (ACR)
             criteria (4 of 11 ACR criteria),

          -  2. SLEDAI ≥4 and ≤10,

          -  3. Positive Anti-nuclear Antibodies (ANA) and/or Positive anti-dsDNA antibodies

          -  4. Male or female between 18 and 50 years of age

          -  5. Current immunity to measles, mumps, rubella and varicella, as evidenced by positive
             IgG titers at the time of screening,

          -  6. For subjects recruited during local influenza season, current vaccination against
             seasonal influenza at least 7 days prior to randomization,

          -  7. Vaccination against H1N1 influenza at least 7 days prior to randomization.

          -  8. For subjects with reproductive potential (males and females), use of a reliable
             means of contraception

          -  9. Written informed consent obtained from the subject.

        Exclusion Criteria:

          -  1. Any serious manifestation of lupus at entry, that, in the opinion of the
             investigator is likely to require initiation of off-protocol medication changes during
             the course of the study and in particular no BILAG A score,

          -  2. Any non-SLE manifestation likely to require, in the investigator's judgment,
             treatment with high-dose corticosteroids or the addition of an immunosuppressive
             regimen during the course of the trial,

          -  3. Received &gt; 20 mg/day of prednisone equivalent for &gt; 7 days during the 30 days prior
             to screening,

          -  4. Currently receiving or having received pulse dose corticosteroids or intravenous
             immunoglobulin (IVIg) within 3 months prior to screening,

          -  5. Received cyclophosphamide within 3 months prior to screening,

          -  6. Received a monoclonal antibody during the 6 months prior to screening,

          -  7. Previously received an investigational treatment directed against IFNa,

          -  8. Received B-cell depleting therapy (e.g. Rituximab) within 12 months

          -  9. Received IV antibiotics during the 30 days prior to screening,

          -  10. Significant electrocardiogram (ECG) abnormalities ,

          -  11. Evidence of any clinically significant abnormality on a chest X-ray which, in the
             opinion of the investigator could represent active infection, latent tuberculosis or
             treatable manifestation of lupus,

          -  12. Any laboratory abnormality that is clinically relevant

          -  13. History of malignancy except completely excised basal cell carcinoma,

          -  14. Congenital immune deficiency,

          -  15. Positive IgM antibody titers in the presence of negative IgG titers to
             Epstein-Barr virus (EBV) or cytomegalovirus (CMV),

          -  16. Frequent recurrences of oral or genital herpes simplex lesions (≥ 6 / year),

          -  17. Episode of shingles within one year of screening,

          -  18. Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV) or HBV (HBsAg,
             anti-HBc ab) positive,

          -  19. Any current signs or symptoms of infection at entry,

          -  20. Administration of any live vaccine within the 3 months prior to study entry

          -  21. Planned use of any investigational or non-registered product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Houssiau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St Luc, Brussels, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Sveti Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Split</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KBC Zagreb</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Kremlin Bicetre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik Gmbh</name>
      <address>
        <city>Bad-Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geneva University Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geneva University Hospital</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

